CARA - Cara Therapeutics, Inc.
IEX Last Trade
0.42
-0.009 -2.071%
Share volume: 6,096
Last Updated: Fri 27 Dec 2024 08:29:25 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$0.43
-0.01
-2.03%
Fundamental analysis
37%
Profitability
25%
Dept financing
11%
Liquidity
75%
Performance
45%
Performance
5 Days
-1.64%
1 Month
56.16%
3 Months
47.51%
6 Months
49.97%
1 Year
-31.85%
2 Year
-95.41%
Key data
Stock price
$0.42
DAY RANGE
$0.43 - $0.46
52 WEEK RANGE
$0.26 - $1.15
52 WEEK CHANGE
-$39.45
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Christopher Posner
Region: US
Website: caratherapeutics.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: caratherapeutics.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Cara Therapeutics, Inc. focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe Pruritus associated with chronic kidney disease (CKD)
Recent news